AGP Executive Report
Last update: 7 hours agoAbortion Access Clash: Liechtenstein’s regent, Hereditary Prince Alois, says he will veto any move to legalise abortion in the first trimester, keeping the country’s very limited exceptions (sexual assault or serious health risk) in place. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement for senaparib, aiming to expand the ovarian cancer maintenance therapy across 66 countries, including Liechtenstein and the wider EEA. Public Health Research: New reporting highlights progress toward a “functional cure” for chronic hepatitis B, noting that millions in the EU/EEA (including Liechtenstein) live with the infection and often only learn after liver damage. Healthcare Data Breach: Brown Health Medical Group-MA says a breach affected 311,000 people, with personal, medical, and financial details potentially accessed. Food Import Rules: UK guidance warns travellers returning from Liechtenstein/Switzerland and other EU-linked countries not to bring back restricted meat and dairy items, with fines possible. Policy & Trade Pressure: Separate coverage notes renewed U.S. tariffs on Switzerland over forced-labour claims—relevant for regional health supply chains and compliance.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
